Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 17 results for fingolimod

  1. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

    Technology appraisal guidance
    Published
    25 April 2012
    View recommendations

    Sections for TA254

  2. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...

    Technology appraisal guidance
    Topic selection

  3. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  4. Cladribine for treating relapsing–remitting multiple sclerosis (TA616)

    Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA616

  5. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533

  6. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  7. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

    Technology appraisal guidance
    Published
    9 June 2021
    View recommendations

    Sections for TA706

  8. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    1 June 2014
    View recommendations

    Sections for TA303

  9. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA699

  10. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 August 2014
    View recommendations

    Sections for TA320

  11. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

    Technology appraisal guidance
    Discontinued

  12. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 June 2018
    View recommendations

    Sections for TA527

  13. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA767

  14. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    None. Source guidance details Comes from guidance Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

    Research recommendation
    Published
    9 June 2015

  15. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    None. Source guidance details Comes from guidance Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

    Research recommendation
    Published
    9 June 2015